Gelonghui February 1st 丨Eling Pharmaceutical (002603.SZ) announced that on February 1, 2023, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration. After review, Ageratum flu granules received on November 14, 2022 met the relevant requirements for drug registration, and agreed to carry out clinical trials for gastrointestinal cold attacks and obstruction in moisture.

Ageratum cold granules are traditional Chinese medicine compound preparations. The proposed functional treatment is to detoxify and relieve moisture. It is used for gastrointestinal colds and wind attacks. Symptoms include fever, bad wind, nasal congestion and runny nose, headache and drowsiness, nausea and vomiting, diarrhea, severe physical distress, abdominal pain, and poor eating.